Aridis Pharmaceuticals (NASDAQ:ARDS) posted its quarterly earnings data on Friday. The company reported ($0.65) EPS for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.10), MarketWatch Earnings reports.
Shares of ARDS opened at $7.21 on Friday. Aridis Pharmaceuticals has a 12-month low of $3.80 and a 12-month high of $10.18. The firm has a market capitalization of $64.34 million, a PE ratio of -2.67 and a beta of 0.11. The stock’s fifty day simple moving average is $7.17 and its 200-day simple moving average is $7.13.
A number of equities analysts have commented on the company. Zacks Investment Research raised Aridis Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, November 10th. Maxim Group reaffirmed a “buy” rating and set a $17.00 price target on shares of Aridis Pharmaceuticals in a research note on Thursday, August 13th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. Aridis Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $15.35.
Aridis Pharmaceuticals, Inc engages in the discovery and development of targeted immunotherapy using fully human monoclonal antibodies, or mAbs, to treat life-threatening infections. Its products include AR-301, AR-105, AR-101, AR-401, AR-201, and AR-501. The company was founded by Eric J. Patzer and Vu L.
Further Reading: How Do Mutual Funds Work?
Receive News & Ratings for Aridis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aridis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.